Update on novel targets and potential treatment avenues in pulmonary hypertension

Research output: Contribution to journalArticle

Abstract

Pulmonary Hypertension (PH) is a condition marked by a combination of constriction and remodeling within the pulmonary vasculature. It remains a disease without a cure, as current treatments were developed with a focus on vasodilatory properties but do not reverse the remodeling component. Numerous recent advances have been made in the understanding of cellular processes that drive pathologic remodeling in each layer of the vessel wall as well as the accompanying maladaptive changes in the right ventricle. In particular, the past few years have yielded much improved insight into the pathways that contribute to altered metabolism, mitochondrial function, and reactive oxygen species signaling and how these pathways promote the proproliferative, promigratory, and antiapoptotic phenotype of the vasculature during PH. Additionally, there have been significant advances in numerous other pathways linked to PH pathogenesis, such as sex hormones and perivascular inflammation. Novel insights into cellular pathology have suggested new avenues for the development of both biomarkers and therapies that will hopefully bring us closer to the elusive goal: A therapy leading to reversal of disease.

Original languageEnglish (US)
Pages (from-to)L811-L831
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume311
Issue number5
DOIs
StatePublished - 2016

Fingerprint

Pulmonary Hypertension
Gonadal Steroid Hormones
Pathologic Processes
Constriction
Heart Ventricles
Reactive Oxygen Species
Biomarkers
Pathology
Inflammation
Phenotype
Lung
Therapeutics

Keywords

  • Pulmonary arterial hypertension
  • Remodeling
  • Vascular

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Cell Biology
  • Physiology (medical)

Cite this

@article{3320f65ecd384a56b54eb44ae51f4bdc,
title = "Update on novel targets and potential treatment avenues in pulmonary hypertension",
abstract = "Pulmonary Hypertension (PH) is a condition marked by a combination of constriction and remodeling within the pulmonary vasculature. It remains a disease without a cure, as current treatments were developed with a focus on vasodilatory properties but do not reverse the remodeling component. Numerous recent advances have been made in the understanding of cellular processes that drive pathologic remodeling in each layer of the vessel wall as well as the accompanying maladaptive changes in the right ventricle. In particular, the past few years have yielded much improved insight into the pathways that contribute to altered metabolism, mitochondrial function, and reactive oxygen species signaling and how these pathways promote the proproliferative, promigratory, and antiapoptotic phenotype of the vasculature during PH. Additionally, there have been significant advances in numerous other pathways linked to PH pathogenesis, such as sex hormones and perivascular inflammation. Novel insights into cellular pathology have suggested new avenues for the development of both biomarkers and therapies that will hopefully bring us closer to the elusive goal: A therapy leading to reversal of disease.",
keywords = "Pulmonary arterial hypertension, Remodeling, Vascular",
author = "John Huetsch and Karthik Suresh and Meghan Bernier and Larissa Shimoda",
year = "2016",
doi = "10.1152/ajplung.00302.2016",
language = "English (US)",
volume = "311",
pages = "L811--L831",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Update on novel targets and potential treatment avenues in pulmonary hypertension

AU - Huetsch, John

AU - Suresh, Karthik

AU - Bernier, Meghan

AU - Shimoda, Larissa

PY - 2016

Y1 - 2016

N2 - Pulmonary Hypertension (PH) is a condition marked by a combination of constriction and remodeling within the pulmonary vasculature. It remains a disease without a cure, as current treatments were developed with a focus on vasodilatory properties but do not reverse the remodeling component. Numerous recent advances have been made in the understanding of cellular processes that drive pathologic remodeling in each layer of the vessel wall as well as the accompanying maladaptive changes in the right ventricle. In particular, the past few years have yielded much improved insight into the pathways that contribute to altered metabolism, mitochondrial function, and reactive oxygen species signaling and how these pathways promote the proproliferative, promigratory, and antiapoptotic phenotype of the vasculature during PH. Additionally, there have been significant advances in numerous other pathways linked to PH pathogenesis, such as sex hormones and perivascular inflammation. Novel insights into cellular pathology have suggested new avenues for the development of both biomarkers and therapies that will hopefully bring us closer to the elusive goal: A therapy leading to reversal of disease.

AB - Pulmonary Hypertension (PH) is a condition marked by a combination of constriction and remodeling within the pulmonary vasculature. It remains a disease without a cure, as current treatments were developed with a focus on vasodilatory properties but do not reverse the remodeling component. Numerous recent advances have been made in the understanding of cellular processes that drive pathologic remodeling in each layer of the vessel wall as well as the accompanying maladaptive changes in the right ventricle. In particular, the past few years have yielded much improved insight into the pathways that contribute to altered metabolism, mitochondrial function, and reactive oxygen species signaling and how these pathways promote the proproliferative, promigratory, and antiapoptotic phenotype of the vasculature during PH. Additionally, there have been significant advances in numerous other pathways linked to PH pathogenesis, such as sex hormones and perivascular inflammation. Novel insights into cellular pathology have suggested new avenues for the development of both biomarkers and therapies that will hopefully bring us closer to the elusive goal: A therapy leading to reversal of disease.

KW - Pulmonary arterial hypertension

KW - Remodeling

KW - Vascular

UR - http://www.scopus.com/inward/record.url?scp=84994577414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994577414&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00302.2016

DO - 10.1152/ajplung.00302.2016

M3 - Article

C2 - 27591245

AN - SCOPUS:84994577414

VL - 311

SP - L811-L831

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 5

ER -